Once the data had been reviewed it was decided that the data from all 3 late-phase clinical trials of dolutegravir would be included to provide the most comprehensive picture, that could allow users to switch between each trial and compare against the current HIV treatment landscape. We would also allow the user to explore data from various stages across each trial, with filters applied to provide a deeper understanding of results across specific demographics.

There was a lot of discussion, particularly about how best to display adverse events data, that would allow users to see what specific side effects were reported across the different studies versus the wider treatment landscape, as this is an area where the ViiV treatment has proven superior to its competitors.

After further refinements and meetings with GSK, ViiV and our partners Pharmiweb, final design recommendations were signed off and the development team went into production of the final version, with the entire process taking less than 3 months to complete.